Efficacy and Safety of Once-Weekly Semaglutide vs. Once-Daily Sitagliptin as Add-On to Metformin in Subjects with Type 2 Diabetes (SUSTAIN China MRCT): A 30-Week Double-Blind, Phase 3a, Randomised Trial
- Resource Type
- Journal
- Source
DIABETES ; JUN 2020, 69 3p. Supplement: 1- Subject
- Language
- English
- ISSN
- 1939327X